-
1
-
-
19944434116
-
Mastocytosis: Pathology, genetics, and current options for therapy
-
Valent P, Akin C, Sperr WR, et al. Mastocytosis: pathology, genetics, and current options for therapy. Leuk Lymphoma. 2005; 46: 35-48.
-
(2005)
Leuk Lymphoma.
, vol.46
, pp. 35-48
-
-
Valent, P.1
Akin, C.2
Sperr, W.R.3
-
2
-
-
21344439293
-
Systemic mastocytosis: Bone marrow pathology, classification, and current therapies
-
DOI 10.1159/000085561
-
Pardanani A,. Systemic mastocytosis: bone marrow pathology, classification, and current therapies. Acta Haematol. 2005; 114: 41-51. (Pubitemid 40911571)
-
(2005)
Acta Haematologica
, vol.114
, Issue.1
, pp. 41-51
-
-
Pardanani, A.1
-
3
-
-
61549132662
-
Mastocytosis
-
Swerdlow S.H. Campo E. Harris N.L. et al, eds. 4th ed. Lyon, France: IARC Press.
-
Horny H, Metcalfe, DD, Bennett, JM, et al. Mastocytosis. In:, Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008: 54-63.
-
(2008)
WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues
, pp. 54-63
-
-
Horny, H.1
Metcalfe, D.D.2
Bennett, J.M.3
-
4
-
-
67651120132
-
Systemic mastocytosis in 342 consecutive adults: Survival studies and prognostic factors
-
Lim KH, Tefferi A, Lasho TL, et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood. 2009; 113: 5727-5736.
-
(2009)
Blood.
, vol.113
, pp. 5727-5736
-
-
Lim, K.H.1
Tefferi, A.2
Lasho, T.L.3
-
5
-
-
74949103091
-
WHO subvariants of indolent mastocytosis: Clinical details and prognostic evaluation in 159 consecutive adults
-
Pardanani A, Lim KH, Lasho TL, et al. WHO subvariants of indolent mastocytosis: clinical details and prognostic evaluation in 159 consecutive adults. Blood. 2010; 115: 150-151.
-
(2010)
Blood.
, vol.115
, pp. 150-151
-
-
Pardanani, A.1
Lim, K.H.2
Lasho, T.L.3
-
6
-
-
79952346791
-
Isolated bone marrow mastocytosis: An underestimated subvariant of indolent systemic mastocytosis
-
Zanotti R, Bonadonna P, Bonifacio M, et al. Isolated bone marrow mastocytosis: an underestimated subvariant of indolent systemic mastocytosis. Haematologica. 2011; 96: 482-484.
-
(2011)
Haematologica.
, vol.96
, pp. 482-484
-
-
Zanotti, R.1
Bonadonna, P.2
Bonifacio, M.3
-
7
-
-
77952745200
-
Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms
-
Alvarez-Twose I, Gonzalez de Olano D, Sanchez-Munoz L, et al. Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms. J Allergy Clin Immunol. 2010; 125: 1269-1278.
-
(2010)
J Allergy Clin Immunol.
, vol.125
, pp. 1269-1278
-
-
Alvarez-Twose, I.1
Gonzalez De Olano, D.2
Sanchez-Munoz, L.3
-
8
-
-
77949268924
-
Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes
-
Teodosio C, Garcia-Montero AC, Jara-Acevedo M, et al. Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes. J Allergy Clin Immunol. 2010; 125: 719-726.
-
(2010)
J Allergy Clin Immunol.
, vol.125
, pp. 719-726
-
-
Teodosio, C.1
Garcia-Montero, A.C.2
Jara-Acevedo, M.3
-
9
-
-
69349102308
-
Prognosis in adult indolent systemic mastocytosis: A long-term study of the Spanish Network on Mastocytosis in a series of 145 patients
-
Escribano L, Alvarez-Twose I, Sanchez-Munoz L, et al. Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. J Allergy Clin Immunol. 2009; 124: 514-521.
-
(2009)
J Allergy Clin Immunol.
, vol.124
, pp. 514-521
-
-
Escribano, L.1
Alvarez-Twose, I.2
Sanchez-Munoz, L.3
-
10
-
-
0034983045
-
Diagnostic criteria and classification of mastocytosis: A consensus proposal
-
DOI 10.1016/S0145-2126(01)00038-8, PII S0145212601000388
-
Valent P, Horny HP, Escribano L, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res. 2001; 25: 603-625. (Pubitemid 32506768)
-
(2001)
Leukemia Research
, vol.25
, Issue.7
, pp. 603-625
-
-
Valent, P.1
Horny, H.-P.2
Escribano, L.3
Longley, B.J.4
Li, C.Y.5
Schwartz, L.B.6
Marone, G.7
Nunez, R.8
Akin, C.9
Sotlar, K.10
Sperr, W.R.11
Wolff, K.12
Brunning, R.D.13
Parwaresch, R.M.14
Austen, K.F.15
Lennert, K.16
Metcalfe, D.D.17
Vardiman, J.W.18
Bennett, J.M.19
-
11
-
-
33748615147
-
Molecular diagnosis of mast cell disorders: A paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology
-
DOI 10.2353/jmoldx.2006.060022
-
Akin C,. Molecular diagnosis of mast cell disorders: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology. J Mol Diagn. 2006; 8: 412-419. (Pubitemid 44377921)
-
(2006)
Journal of Molecular Diagnostics
, vol.8
, Issue.4
, pp. 412-419
-
-
Akin, C.1
-
12
-
-
70449706224
-
Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies
-
Pardanani A, Lim KH, Lasho TL, et al. Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies. Blood. 2009; 114: 3769-3772.
-
(2009)
Blood.
, vol.114
, pp. 3769-3772
-
-
Pardanani, A.1
Lim, K.H.2
Lasho, T.L.3
-
13
-
-
0034766591
-
Bone marrow mast cell morphologic features and hematopoietic dyspoiesis in systemic mast cell disease
-
DOI 10.1309/Q2WJ-46CL-YRFT-M5JF
-
Stevens EC, Rosenthal NS,. Bone marrow mast cell morphologic features and hematopoietic dyspoiesis in systemic mast cell disease. Am J Clin Pathol. 2001; 116: 177-182. (Pubitemid 33044321)
-
(2001)
American Journal of Clinical Pathology
, vol.116
, Issue.2
, pp. 177-182
-
-
Stevens, E.C.1
Rosenthal, N.S.2
-
14
-
-
2942596256
-
Bone marrow mast cell immunophenotyping in adults with mast cell disease: A prospective study of 33 patients
-
DOI 10.1016/j.leukres.2003.10.035, PII S0145212603004168
-
Pardanani A, Kimlinger T, Reeder T, Li CY, Tefferi A,. Bone marrow mast cell immunophenotyping in adults with mast cell disease: a prospective study of 33 patients. Leuk Res. 2004; 28: 777-783. (Pubitemid 38760039)
-
(2004)
Leukemia Research
, vol.28
, Issue.8
, pp. 777-783
-
-
Pardanani, A.1
Kimlinger, T.2
Reeder, T.3
Li, C.-Y.4
Tefferi, A.5
-
15
-
-
33846099538
-
FIP1L1/PDGFRA is a molecular marker of chronic eosinophilic leukaemia but not for systemic mastocytosis [1]
-
DOI 10.1111/j.1365-2362.2007.01757.x
-
Valent P, Akin C, Metcalfe DD,. FIP1L1/PDGFRA is a molecular marker of chronic eosinophilic leukaemia but not for systemic mastocytosis. Eur J Clin Invest. 2007; 37: 153-154. (Pubitemid 46066495)
-
(2007)
European Journal of Clinical Investigation
, vol.37
, Issue.2
, pp. 153-154
-
-
Valent, P.1
Akin, C.2
Metcalfe, D.D.3
-
16
-
-
58149161786
-
Utility of the World Heath Organization classification criteria for the diagnosis of systemic mastocytosis in bone marrow
-
Johnson MR, Verstovsek S, Jorgensen JL, et al. Utility of the World Heath Organization classification criteria for the diagnosis of systemic mastocytosis in bone marrow. Mod Pathol. 2009; 22: 50-57.
-
(2009)
Mod Pathol.
, vol.22
, pp. 50-57
-
-
Johnson, M.R.1
Verstovsek, S.2
Jorgensen, J.L.3
-
17
-
-
67049095733
-
Mastocytosis. A disease of the hematopoietic stem cell
-
Homann J, Kolck U, Molderings GJ,. Mastocytosis. A disease of the hematopoietic stem cell. Dtsch Arztebl Int. 2009; 106: 173-174.
-
(2009)
Dtsch Arztebl Int.
, vol.106
, pp. 173-174
-
-
Homann, J.1
Kolck, U.2
Molderings, G.J.3
-
18
-
-
34548690793
-
Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with "idiopathic" anaphylaxis
-
DOI 10.1182/blood-2006-06-028100
-
Akin C, Scott LM, Kocabas CN, et al. Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with "idiopathic" anaphylaxis. Blood. 2007; 110: 2331-2333. (Pubitemid 47523152)
-
(2007)
Blood
, vol.110
, Issue.7
, pp. 2331-2333
-
-
Akin, C.1
Scott, L.M.2
Kocabas, C.N.3
Kushnir-Sukhov, N.4
Brittain, E.5
Noel, P.6
Metcalfe, D.D.7
-
19
-
-
77949865698
-
Variable presence of KITD816V in clonal haematological non-mast lineage diseases associated with systemic mastocytosis (SM-AHNMD)
-
Sotlar K, Colak S, Bache A, et al. Variable presence of KITD816V in clonal haematological non-mast lineage diseases associated with systemic mastocytosis (SM-AHNMD). J Pathol. 2010; 220: 586-595.
-
(2010)
J Pathol.
, vol.220
, pp. 586-595
-
-
Sotlar, K.1
Colak, S.2
Bache, A.3
-
20
-
-
78649498791
-
Phenotypic heterogeneity, novel diagnostic markers, and target expression profiles in normal and neoplastic human mast cells
-
Valent P, Cerny-Reiterer S, Herrmann H, et al. Phenotypic heterogeneity, novel diagnostic markers, and target expression profiles in normal and neoplastic human mast cells. Best Pract Res Clin Haematol. 2010; 23: 369-378.
-
(2010)
Best Pract Res Clin Haematol.
, vol.23
, pp. 369-378
-
-
Valent, P.1
Cerny-Reiterer, S.2
Herrmann, H.3
-
21
-
-
38549127753
-
How we diagnose and treat WHO-defined systemic mastocytosis in adults
-
DOI 10.3324/haematol.12324
-
Tefferi A, Verstovsek S, Pardanani A,. How we diagnose and treat WHO-defined systemic mastocytosis in adults. Haematologica. 2008; 93: 6-9. (Pubitemid 351156144)
-
(2008)
Haematologica
, vol.93
, Issue.1
, pp. 6-9
-
-
Tefferi, A.1
Verstovsek, S.2
Pardanani, A.3
-
22
-
-
0018096538
-
Decrease of mast cells in W/W(V) mice and their increase by bone marrow transplantation
-
Kitamura Y, Go S, Hatanaka K,. Decrease of mast cells in W/Wv mice and their increase by bone marrow transplantation. Blood. 1978; 52: 447-452. (Pubitemid 8395558)
-
(1978)
Blood
, vol.52
, Issue.2
, pp. 447-452
-
-
Kitamura, Y.1
Go, S.2
Hatanaka, K.3
-
23
-
-
0018344526
-
Decreased production of mast cells in S1/S1(d) anemic mice
-
Kitamura Y, Go S,. Decreased production of mast cells in S1/S1d anemic mice. Blood. 1979; 53: 492-497. (Pubitemid 9140406)
-
(1979)
Blood
, vol.53
, Issue.3
, pp. 492-497
-
-
Kitamura, Y.1
Go, S.2
-
24
-
-
0028856070
-
Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder
-
Nagata H, Worobec AS, Oh CK, et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S A. 1995; 92: 10560-10564.
-
(1995)
Proc Natl Acad Sci U S A.
, vol.92
, pp. 10560-10564
-
-
Nagata, H.1
Worobec, A.S.2
Oh, C.K.3
-
25
-
-
0009013631
-
Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: Establishment of clonality in a human mast cell neoplasm
-
DOI 10.1038/ng0396-312
-
Longley BJ, Tyrrell L, Lu SZ, et al. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat Genet. 1996; 12: 312-314. (Pubitemid 26080092)
-
(1996)
Nature Genetics
, vol.12
, Issue.3
, pp. 312-314
-
-
Longley, B.J.1
Tyrrell, L.2
Lu, S.-Z.3
Ma, Y.-S.4
Langley, K.5
Ding, T.-G.6
Duffy, T.7
Jacobs, P.8
Tang, L.H.9
Modlin, I.10
-
26
-
-
44849118922
-
Phenotypic and genotypic characteristics of mastocytosis according to the age of onset [serial online]
-
Lanternier F, Cohen-Akenine A, Palmerini F, et al. Phenotypic and genotypic characteristics of mastocytosis according to the age of onset [serial online]. PLoS One. 2008; 3: e1906.
-
(2008)
PLoS One.
, vol.3
-
-
Lanternier, F.1
Cohen-Akenine, A.2
Palmerini, F.3
-
27
-
-
0042357240
-
Structure of a c-Kit product complex reveals the basis for kinase transactivation
-
DOI 10.1074/jbc.C300186200
-
Mol CD, Lim KB, Sridhar V, et al. Structure of a c-kit product complex reveals the basis for kinase transactivation. J Biol Chem. 2003; 278: 31461-31464. (Pubitemid 37048320)
-
(2003)
Journal of Biological Chemistry
, vol.278
, Issue.34
, pp. 31461-31464
-
-
Mol, C.D.1
Lim, K.B.2
Sridhar, V.3
Zou, H.4
Chien, E.Y.T.5
Sang, B.-C.6
Nowakowski, J.7
Kassel, D.B.8
Cronin, C.N.9
McRee, D.E.10
-
28
-
-
0027359443
-
Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product
-
Furitsu T, Tsujimura T, Tono T, et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest. 1993; 92: 1736-1744. (Pubitemid 23304537)
-
(1993)
Journal of Clinical Investigation
, vol.92
, Issue.4
, pp. 1736-1744
-
-
Furitsu, T.1
Tsujimura, T.2
Tono, T.3
Ikeda, H.4
Kitayama, H.5
Koshimizu, U.6
Sugahara, H.7
Butterfield, J.H.8
Ashman, L.K.9
Kanayama, Y.10
Matsuzawa, Y.11
Kitamura, Y.12
Kanakura, Y.13
-
29
-
-
3442893823
-
The biology of Kit in disease and the application of pharmacogenetics
-
DOI 10.1016/j.jaci.2004.04.046, PII S0091674904014174
-
Akin C, Metcalfe DD,. The biology of Kit in disease and the application of pharmacogenetics. J Allergy Clin Immunol. 2004; 114: 13-19; quiz 20. (Pubitemid 39005112)
-
(2004)
Journal of Allergy and Clinical Immunology
, vol.114
, Issue.1
, pp. 13-19
-
-
Akin, C.1
Metcalfe, D.D.2
-
30
-
-
54349125809
-
Delineation of the KIT-independent oncogenic pathway in neoplastic mast cells that involves Lyn and Btk and can be disrupted with the KIT/Lyn/Btk-targeting drug dasatinib
-
Gleixner K, Mayerhofer M, Rix U, et al. Delineation of the KIT-independent oncogenic pathway in neoplastic mast cells that involves Lyn and Btk and can be disrupted with the KIT/Lyn/Btk-targeting drug dasatinib. Blood. 2007; 110: 460a-461a.
-
(2007)
Blood.
, vol.110
-
-
Gleixner, K.1
Mayerhofer, M.2
Rix, U.3
-
32
-
-
67349145955
-
Frequent TET2 mutations in systemic mastocytosis: Clinical, KITD816V and FIP1L1-PDGFRA correlates
-
Tefferi A, Levine RL, Lim KH, et al. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia. 2009; 23: 900-904.
-
(2009)
Leukemia.
, vol.23
, pp. 900-904
-
-
Tefferi, A.1
Levine, R.L.2
Lim, K.H.3
-
33
-
-
84983656671
-
New TET2, ASXL1, and CBL mutations have poor prognostic impact in systemic mastocytosis and related disorders [abstract]
-
Abstract 3076.
-
Traina F, Jankowska A, Makishima H, et al. New TET2, ASXL1, and CBL mutations have poor prognostic impact in systemic mastocytosis and related disorders [abstract]. Blood (ASH Annual Meeting Abstracts). 2010; 116. Abstract 3076.
-
(2010)
Blood (ASH Annual Meeting Abstracts).
, vol.116
-
-
Traina, F.1
Jankowska, A.2
Makishima, H.3
-
34
-
-
79952336888
-
Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis
-
Wilson T, Maric I, Simakova O, et al. Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis. Haematologica. 2011; 96: 459-463.
-
(2011)
Haematologica.
, vol.96
, pp. 459-463
-
-
Wilson, T.1
Maric, I.2
Simakova, O.3
-
35
-
-
78651060064
-
Gene expression profile, pathways, and transcriptional system regulation in indolent systemic mastocytosis
-
Niedoszytko M, Oude Elberink JN, Bruinenberg M, et al. Gene expression profile, pathways, and transcriptional system regulation in indolent systemic mastocytosis. Allergy. 2011; 66: 229-237.
-
(2011)
Allergy.
, vol.66
, pp. 229-237
-
-
Niedoszytko, M.1
Oude Elberink, J.N.2
Bruinenberg, M.3
-
37
-
-
34249787870
-
Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis
-
DOI 10.1016/j.jaci.2007.03.032, PII S0091674907006343
-
Carter MC, Robyn JA, Bressler PB, Walker JC, Shapiro GG, Metcalfe DD,. Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis. J Allergy Clin Immunol. 2007; 119: 1550-1551. (Pubitemid 46855867)
-
(2007)
Journal of Allergy and Clinical Immunology
, vol.119
, Issue.6
, pp. 1550-1551
-
-
Carter, M.C.1
Robyn, J.A.2
Bressler, P.B.3
Walker, J.C.4
Shapiro, G.G.5
Metcalfe, D.D.6
-
38
-
-
34250826484
-
Successful treatment of cutaneous mastocytosis and Méniere disease with anti-IgE therapy
-
DOI 10.1016/j.jaci.2007.05.011, PII S0091674907009566
-
Siebenhaar F, Kuhn W, Zuberbier T, Maurer M,. Successful treatment of cutaneous mastocytosis and Meniere disease with anti-IgE therapy. J Allergy Clin Immunol. 2007; 120: 213-215. (Pubitemid 46990509)
-
(2007)
Journal of Allergy and Clinical Immunology
, vol.120
, Issue.1
, pp. 213-215
-
-
Siebenhaar, F.1
Kuhn, W.2
Zuberbier, T.3
Maurer, M.4
-
39
-
-
0031943841
-
Response of severe systemic mastocytosis to interferon alpha
-
DOI 10.1046/j.1365-2133.1998.02131.x
-
Butterfield JH,. Response of severe systemic mastocytosis to interferon alpha. Br J Dermatol. 1998; 138: 489-495. (Pubitemid 28145521)
-
(1998)
British Journal of Dermatology
, vol.138
, Issue.3
, pp. 489-495
-
-
Butterfield, J.H.1
-
40
-
-
0036454699
-
Treatment of adult systemic mastocytosis with interferon-α: Results of a multicentre phase II trial on 20 patients
-
DOI 10.1046/j.1365-2141.2002.03944.x
-
Casassus P, Caillat-Vigneron N, Martin A, et al. Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patients. Br J Haematol. 2002; 119: 1090-1097. (Pubitemid 35463838)
-
(2002)
British Journal of Haematology
, vol.119
, Issue.4
, pp. 1090-1097
-
-
Casassus, P.1
Caillat-Vigneron, N.2
Martin, A.3
Simon, J.4
Gallais, V.5
Beaudry, P.6
Eclache, V.7
Laroche, L.8
Lortholary, P.9
Raphael, M.10
Guillevin, L.11
Lortholary, O.12
-
41
-
-
0346154747
-
Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: Report of five cases and review of the literature
-
DOI 10.1016/S0145-2126(03)00259-5
-
Hauswirth AW, Simonitsch-Klupp I, Uffmann M, et al. Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of 5 cases and review of the literature. Leuk Res. 2004; 28: 249-257. (Pubitemid 37550059)
-
(2004)
Leukemia Research
, vol.28
, Issue.3
, pp. 249-257
-
-
Hauswirth, A.W.1
Simonitsch-Klupp, I.2
Uffmann, M.3
Koller, E.4
Sperr, W.R.5
Lechner, K.6
Valent, P.7
-
42
-
-
73349111582
-
Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine
-
Lim KH, Pardanani A, Butterfield JH, Li CY, Tefferi A,. Cytoreductive therapy in 108 adults with systemic mastocytosis: outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine. Am J Hematol. 2009; 84: 790-794.
-
(2009)
Am J Hematol.
, vol.84
, pp. 790-794
-
-
Lim, K.H.1
Pardanani, A.2
Butterfield, J.H.3
Li, C.Y.4
Tefferi, A.5
-
43
-
-
84858268181
-
Long term efficacy and safety of cladribine in adult systemic mastocytosis: A French multicenter study of 44 patients [abstract]
-
Abstract 1982.
-
Hermine O, Hirsh I, Damaj G, et al. Long term efficacy and safety of cladribine in adult systemic mastocytosis: a French multicenter study of 44 patients [abstract]. Blood (ASH Annual Meeting Abstracts). 2010; 116. Abstract 1982.
-
(2010)
Blood (ASH Annual Meeting Abstracts).
, vol.116
-
-
Hermine, O.1
Hirsh, I.2
Damaj, G.3
-
44
-
-
20144379077
-
Efficacy and safety of cladribine in adult systemic mastocytosis: A French multicenter study of 33 patients [abstract]
-
Abstract 661.
-
Lortholary O, Vargaftig J, Feger F, et al. Efficacy and safety of cladribine in adult systemic mastocytosis: a French multicenter study of 33 patients [abstract]. Blood (ASH Annual Meeting Abstracts). 2004; 104. Abstract 661.
-
(2004)
Blood (ASH Annual Meeting Abstracts).
, vol.104
-
-
Lortholary, O.1
Vargaftig, J.2
Feger, F.3
-
45
-
-
0345167915
-
Cladribine therapy for systemic mastocytosis
-
DOI 10.1182/blood-2003-05-1699
-
Kluin-Nelemans HC, Oldhoff JM, Van Doormaal JJ, et al. Cladribine therapy for systemic mastocytosis. Blood. 2003; 102: 4270-4276. (Pubitemid 37494083)
-
(2003)
Blood
, vol.102
, Issue.13
, pp. 4270-4276
-
-
Kluin-Nelemans, H.C.1
Oldhoff, J.M.2
Van Doormaal, J.J.3
Van't Wout, J.W.4
Verhoef, G.5
Gerrits, W.B.J.6
Van Dobbenburgh, O.A.7
Pasmans, S.G.8
Fijnheer, R.9
-
46
-
-
33749368009
-
KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: A prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients
-
DOI 10.1182/blood-2006-04-015545
-
Garcia-Montero AC, Jara-Acevedo M, Teodosio C, et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood. 2006; 108: 2366-2372. (Pubitemid 44497521)
-
(2006)
Blood
, vol.108
, Issue.7
, pp. 2366-2372
-
-
Garcia-Montero, A.C.1
Jara-Acevedo, M.2
Teodosio, C.3
Sanchez, M.L.4
Nunez, R.5
Prados, A.6
Aldanondo, I.7
Sanchez, L.8
Dominguez, M.9
Botana, L.M.10
Sanchez-Jimenez, F.11
Sotlar, K.12
Almeida, J.13
Escribano, L.14
Orfao, A.15
-
47
-
-
33749627742
-
Novel approaches in the treatment of systemic mastocytosis
-
DOI 10.1002/cncr.22187
-
Quintas-Cardama A, Aribi A, Cortes J, Giles FJ, Kantarjian H, Verstovsek S,. Novel approaches in the treatment of systemic mastocytosis. Cancer. 2006; 107: 1429-1439. (Pubitemid 44546901)
-
(2006)
Cancer
, vol.107
, Issue.7
, pp. 1429-1439
-
-
Quintas-Cardama, A.1
Aribi, A.2
Cortes, J.3
Giles, F.J.4
Kantarjian, H.5
Verstovsek, S.6
-
48
-
-
0034254249
-
Inhibition of c-kit receptor tyrosine kinase activity by STI 571 a selective tyrosine kinase inhibitor
-
Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ,. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 2000; 96: 925-932. (Pubitemid 30618049)
-
(2000)
Blood
, vol.96
, Issue.3
, pp. 925-932
-
-
Heinrich, M.C.1
Griffith, D.J.2
Druker, B.J.3
Wait, C.L.4
Ott, K.A.5
Zigler, A.J.6
-
49
-
-
0043169405
-
Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit
-
DOI 10.1016/S0301-472X(03)00112-7
-
Akin C, Brockow K, D'Ambrosio C, et al. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Exp Hematol. 2003; 31: 686-692. (Pubitemid 36945381)
-
(2003)
Experimental Hematology
, vol.31
, Issue.8
, pp. 686-692
-
-
Akin, C.1
Brockow, K.2
D'Ambrosio, C.3
Kirshenbaum, A.S.4
Ma, Y.5
Longley, B.J.6
Metcalfe, D.D.7
-
50
-
-
68649118339
-
Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis
-
Vega-Ruiz A, Cortes JE, Sever M, et al. Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. Leuk Res. 2009; 33: 1481-1484.
-
(2009)
Leuk Res.
, vol.33
, pp. 1481-1484
-
-
Vega-Ruiz, A.1
Cortes, J.E.2
Sever, M.3
-
51
-
-
33745863150
-
Imatinib mesylate in the treatment of systemic mastocytosis: A phase II trial
-
DOI 10.1002/cncr.21996
-
Droogendijk HJ, Kluin-Nelemans HJ, van Doormaal JJ, Oranje AP, van de Loosdrecht AA, van Daele PL,. Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial. Cancer. 2006; 107: 345-351. (Pubitemid 44036564)
-
(2006)
Cancer
, vol.107
, Issue.2
, pp. 345-351
-
-
Droogendijk, H.J.1
Kluin-Nelemans, H.J.C.2
Van Doormaal, J.J.3
Oranje, A.P.4
Van De Loosdrecht, A.A.5
Van Daele, P.L.A.6
-
52
-
-
33947520803
-
Juxtamembrane-type c-kit gene mutation found in aggressive systemic mastocytosis induces imatinib-resistant constitutive KIT activation
-
DOI 10.1038/labinvest.3700524, PII 3700524
-
Nakagomi N, Hirota S,. Juxtamembrane-type c-kit gene mutation found in aggressive systemic mastocytosis induces imatinib-resistant constitutive KIT activation. Lab Invest. 2007; 87: 365-371. (Pubitemid 46474567)
-
(2007)
Laboratory Investigation
, vol.87
, Issue.4
, pp. 365-371
-
-
Nakagomi, N.1
Hirota, S.2
-
53
-
-
8644263305
-
FIP1L1-PDGFRA fusion: Prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia
-
DOI 10.1182/blood-2004-03-0787
-
Pardanani A, Brockman SR, Paternoster SF, et al. FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood. 2004; 104: 3038-3045. (Pubitemid 39507117)
-
(2004)
Blood
, vol.104
, Issue.10
, pp. 3038-3045
-
-
Pardanani, A.1
Brockman, S.R.2
Paternoster, S.F.3
Flynn, H.C.4
Ketterling, R.P.5
Lasho, T.L.6
Ho, C.-L.7
Li, C.-Y.8
Dewald, G.W.9
Tefferi, A.10
-
54
-
-
52049089936
-
Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases
-
Heinrich MC, Joensuu H, Demetri GD, et al. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. Clin Cancer Res. 2008; 14: 2717-2725.
-
(2008)
Clin Cancer Res.
, vol.14
, pp. 2717-2725
-
-
Heinrich, M.C.1
Joensuu, H.2
Demetri, G.D.3
-
55
-
-
30444446680
-
PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: Comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects
-
DOI 10.1182/blood-2005-07-3022
-
Gleixner K, Mayerhofer M, Aichberger KJ, et al. PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood. 2006; 107: 752-759. (Pubitemid 43076402)
-
(2006)
Blood
, vol.107
, Issue.2
, pp. 752-759
-
-
Gleixner, K.V.1
Mayerhofer, M.2
Aichberger, K.J.3
Derdak, S.4
Sonneck, K.5
Bohm, A.6
Gruze, A.7
Samorapoompichit, P.8
Manley, P.W.9
Fabbro, D.10
Pickl, W.F.11
Sillaber, C.12
Valent, P.13
-
56
-
-
71849087531
-
A phase II study of AMN107, a novel tyrosine kinase inhibitor, administered to patients (pts) with systemic mastocytosis (SM) [abstract]
-
Abstract 6588.
-
Schatz M, Verhoef G, Gattermann N, et al. A phase II study of AMN107, a novel tyrosine kinase inhibitor, administered to patients (pts) with systemic mastocytosis (SM) [abstract]. J Clin Oncol. 2006; 24 (18S). Abstract 6588.
-
(2006)
J Clin Oncol.
, vol.24
, Issue.18
-
-
Schatz, M.1
Verhoef, G.2
Gattermann, N.3
-
57
-
-
19944428353
-
Discovery of N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays
-
DOI 10.1021/jm049486a
-
Lombardo L, Lee FY, Chen P, et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-[4-(2-hydroxyethyl)-piperazin-1-yl]-2-methylpyrimidin-4-ylamino) -thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem. 2004; 47: 6658-6661. (Pubitemid 40053752)
-
(2004)
Journal of Medicinal Chemistry
, vol.47
, Issue.27
, pp. 6658-6661
-
-
Lombardo, L.J.1
Lee, F.Y.2
Chen, P.3
Norris, D.4
Barrish, J.C.5
Behnia, K.6
Castaneda, S.7
Cornelius, L.A.M.8
Das, J.9
Doweyko, A.M.10
Fairchild, C.11
Hunt, J.T.12
Inigo, I.13
Johnston, K.14
Kamath, A.15
Kan, D.16
Klei, H.17
Marathe, P.18
Pang, S.19
Peterson, R.20
Pitt, S.21
Schieven, G.L.22
Schmidt, R.J.23
Tokarski, J.24
Wen, M.-L.25
Wityak, J.26
Borzilleri, R.M.27
more..
-
58
-
-
33645687784
-
D816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis
-
DOI 10.1182/blood-2005-10-3969
-
Shah NP, Lee FY, Luo R, Jiang Y, Donker M, Akin C,. Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood. 2006; 108: 286-291. (Pubitemid 43990640)
-
(2006)
Blood
, vol.108
, Issue.1
, pp. 286-291
-
-
Shah, N.P.1
Lee, F.Y.2
Luo, R.3
Jiang, Y.4
Donker, M.5
Akin, C.6
-
59
-
-
31544459272
-
Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies
-
DOI 10.1158/0008-5472.CAN-05-2050
-
Schittenhelm M, Shiraga S, Schroeder A, et al. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res. 2006; 66: 473-481. (Pubitemid 43166056)
-
(2006)
Cancer Research
, vol.66
, Issue.1
, pp. 473-481
-
-
Schittenhelm, M.M.1
Shiraga, S.2
Schroeder, A.3
Corbin, A.S.4
Griffith, D.5
Lee, F.Y.6
Bokemeyer, C.7
Deininger, M.W.N.8
Druker, B.J.9
Heinrich, M.C.10
-
60
-
-
52449085884
-
Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis
-
Verstovsek S, Tefferi A, Cortes J, et al. Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res. 2008; 14: 3906-3915.
-
(2008)
Clin Cancer Res.
, vol.14
, pp. 3906-3915
-
-
Verstovsek, S.1
Tefferi, A.2
Cortes, J.3
-
61
-
-
54349097778
-
Treatment responses to cladribine and dasatinib in rapidly progressing aggressive mastocytosis
-
Aichberger KJ, Sperr WR, Gleixner KV, Kretschmer A, Valent P,. Treatment responses to cladribine and dasatinib in rapidly progressing aggressive mastocytosis. Eur J Clin Invest. 2008; 38: 869-873.
-
(2008)
Eur J Clin Invest.
, vol.38
, pp. 869-873
-
-
Aichberger, K.J.1
Sperr, W.R.2
Gleixner, K.V.3
Kretschmer, A.4
Valent, P.5
-
62
-
-
41849136506
-
Dasatinib therapy for systemic mastocytosis: Four cases
-
DOI 10.1111/j.1600-0609.2008.01048.x
-
Purtill D, Cooney J, Sinniah R, et al. Dasatinib therapy for systemic mastocytosis: 4 cases. Eur J Haematol. 2008; 80: 456-458. (Pubitemid 351503111)
-
(2008)
European Journal of Haematology
, vol.80
, Issue.5
, pp. 456-458
-
-
Purtill, D.1
Cooney, J.2
Sinniah, R.3
Carnley, B.4
Cull, G.5
Augustson, B.6
Cannell, P.7
-
63
-
-
18844478996
-
PKC412 - A protein kinase inhibitor with a broad therapeutic potential
-
Fabbro D, Ruetz S, Bodis S, et al. PKC412-a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des. 2000; 15: 17-28. (Pubitemid 30364896)
-
(2000)
Anti-Cancer Drug Design
, vol.15
, Issue.1
, pp. 17-28
-
-
Fabbro, D.1
Ruetz, S.2
Bodis, S.3
Pruschy, M.4
Csermak, K.5
Man, A.6
Campochiaro, P.7
Wood, J.8
O'Reilly, T.9
Meyer, T.10
-
64
-
-
36349020293
-
Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT
-
DOI 10.3324/haematol.11339
-
Gleixner KV, Mayerhofer M, Sonneck K, et al. Synergistic growth-inhibitory effects of 2 tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT. Haematologica. 2007; 92: 1451-1459. (Pubitemid 350144119)
-
(2007)
Haematologica
, vol.92
, Issue.11
, pp. 1451-1459
-
-
Gleixner, K.V.1
Mayerhofer, M.2
Sonneck, K.3
Gruze, A.4
Samorapoompichit, P.5
Baumgartner, C.6
Lee, F.Y.7
Aichberger, K.J.8
Manley, P.W.9
Fabbro, D.10
Pickl, W.F.11
Sillaber, C.12
Valent, P.13
-
65
-
-
79960404044
-
KIT inhibitor midostaurin exhibits a high rate of clinically meaningful and durable responses in advanced systemic mastocytosis: Report of a fully accrued phase II trial [abstract]
-
Abstract 316.
-
Gotlib J, DeAngelo DJ, George TI, et al. KIT inhibitor midostaurin exhibits a high rate of clinically meaningful and durable responses in advanced systemic mastocytosis: report of a fully accrued phase II trial [abstract]. Blood (ASH Annual Meeting Abstracts). 2010; 116. Abstract 316.
-
(2010)
Blood (ASH Annual Meeting Abstracts).
, pp. 116
-
-
Gotlib, J.1
Deangelo, D.J.2
George, T.I.3
-
66
-
-
77951066096
-
A critical reappraisal of treatment response criteria in systemic mastocytosis and a proposal for revisions
-
Pardanani A, Tefferi A,. A critical reappraisal of treatment response criteria in systemic mastocytosis and a proposal for revisions. Eur J Haematol. 2010; 84: 371-378.
-
(2010)
Eur J Haematol.
, vol.84
, pp. 371-378
-
-
Pardanani, A.1
Tefferi, A.2
-
67
-
-
70349658639
-
Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT [serial online]
-
Dubreuil P, Letard S, Ciufolini M, et al. Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT [serial online]. PLoS One. 2009; 4: e7258.
-
(2009)
PLoS One.
, vol.4
-
-
Dubreuil, P.1
Letard, S.2
Ciufolini, M.3
-
68
-
-
57149112342
-
Masitinib is safe and effective for the treatment of canine mast cell tumors
-
Hahn KA, Ogilvie G, Rusk T, et al. Masitinib is safe and effective for the treatment of canine mast cell tumors. J Vet Intern Med. 2008; 22: 1301-1309.
-
(2008)
J Vet Intern Med.
, vol.22
, pp. 1301-1309
-
-
Hahn, K.A.1
Ogilvie, G.2
Rusk, T.3
-
69
-
-
78649504351
-
Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: A phase 2a study
-
Paul C, Sans B, Suarez F, et al. Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study. Am J Hematol. 2010; 85: 921-925.
-
(2010)
Am J Hematol.
, vol.85
, pp. 921-925
-
-
Paul, C.1
Sans, B.2
Suarez, F.3
-
70
-
-
31544481378
-
OSI-930: A novel selective inhibitor of kit and kinase insert domain receptor tyrosine kinases with antitumor activity in mouse xenograft models
-
DOI 10.1158/0008-5472.CAN-05-2873
-
Garton AJ, Crew AP, Franklin M, et al. OSI-930: a novel selective inhibitor of Kit and kinase insert domain receptor tyrosine kinases with antitumor activity in mouse xenograft models. Cancer Res. 2006; 66: 1015-1024. (Pubitemid 43165969)
-
(2006)
Cancer Research
, vol.66
, Issue.2
, pp. 1015-1024
-
-
Garton, A.J.1
Crew, A.P.A.2
Franklin, M.3
Cooke, A.R.4
Wynne, G.M.5
Castaldo, L.6
Kahler, J.7
Winski, S.L.8
Franks, A.9
Brown, E.N.10
Bittner, M.A.11
Keily, J.F.12
Briner, P.13
Hidden, C.14
Srebernak, M.C.15
Pirrit, C.16
O'Connor, M.17
Chan, A.18
Vulevic, B.19
Henninger, D.20
Hart, K.21
Sennello, R.22
Li, A.-H.23
Zhang, T.24
Richardson, F.25
Emerson, D.L.26
Castelhano, A.L.27
Arnold, L.D.28
Gibson, N.W.29
more..
-
71
-
-
0013102301
-
CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML)
-
DOI 10.1016/S1535-6108(02)00070-3
-
Kelly L, Yu JC, Boulton CL, et al. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell. 2002; 1: 421-432. (Pubitemid 41039123)
-
(2002)
Cancer Cell
, vol.1
, Issue.5
, pp. 421-432
-
-
Kelly, L.M.1
Yu, J.-C.2
Boulton, C.L.3
Apatira, M.4
Li, J.5
Sullivan, C.M.6
Williams, I.7
Amaral, S.M.8
Curley, D.P.9
Duclos, N.10
Neuberg, D.11
Scarborough, R.M.12
Pandey, A.13
Hollenbach, S.14
Abe, K.15
Lokker, N.A.16
Gilliland, D.G.17
Giese, N.A.18
-
72
-
-
0034095603
-
The pyrido[2,3-d]pyrimidine derivative PD180970 inhibits p210(Bcr-Abl) tyrosine kinase and induces apoptosis of K562 leukemic cells
-
Dorsey J, Jove R, Kraker AJ, et al. The pyrido[2,3-d]pyrimidine derivative PD180970 inhibits p210 Bcr-Abl tyrosine kinase and induces apoptosis of K562 leukemic cells. Cancer Res. 2000; 60: 3127-3131. (Pubitemid 30407904)
-
(2000)
Cancer Research
, vol.60
, Issue.12
, pp. 3127-3131
-
-
Dorsey, J.F.1
Jove, R.2
Kraker, A.J.3
Wu, J.4
-
73
-
-
0036682230
-
Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases
-
Wisniewski D, Lambek CL, Liu C, et al. Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases. Cancer Res. 2002; 62: 4244-4255. (Pubitemid 34827279)
-
(2002)
Cancer Research
, vol.62
, Issue.15
, pp. 4244-4255
-
-
Wisniewski, D.1
Lambek, C.L.2
Liu, C.3
Strife, A.4
Veach, D.R.5
Nagar, B.6
Young, M.A.7
Schindler, T.8
Bornmann, W.G.9
Bertino, J.R.10
Kuriyan, J.11
Clarkson, B.12
-
74
-
-
22044443112
-
In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit
-
DOI 10.1182/blood-2004-12-4771
-
Corbin A, Demehri S, Griswold IJ, et al. In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit. Blood. 2005; 106: 227-234. (Pubitemid 40967197)
-
(2005)
Blood
, vol.106
, Issue.1
, pp. 227-234
-
-
Corbin, A.S.1
Demehri, S.2
Griswold, I.J.3
Wang, Y.4
Metcalf III, C.A.5
Sundaramoorthi, R.6
Shakespeare, W.C.7
Snodgrass, J.8
Wardwell, S.9
Dalgarno, D.10
Iuliucci, J.11
Sawyer, T.K.12
Heinrich, M.C.13
Druker, B.J.14
Deininger, M.W.N.15
-
75
-
-
0037100281
-
Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors
-
DOI 10.1182/blood-2001-12-0350
-
Liao A, Chien MB, Shenoy N, et al. Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors. Blood. 2002; 100: 585-593. (Pubitemid 34761123)
-
(2002)
Blood
, vol.100
, Issue.2
, pp. 585-593
-
-
Liao, A.T.1
Chien, M.B.2
Shenoy, N.3
Mendel, D.B.4
McMahon, G.5
Cherrington, J.M.6
London, C.A.7
-
76
-
-
0037401818
-
Tricyclic quinoxalines as potent kinase inhibitors of PDGFR kinase, Flt3 and Kit
-
DOI 10.1016/S0968-0896(03)00048-8
-
Gazit A, Yee K, Uecker A, et al. Tricyclic quinoxalines as potent kinase inhibitors of PDGFR kinase, Flt3 and Kit. Bioorg Med Chem. 2003; 11: 2007-2018. (Pubitemid 36379018)
-
(2003)
Bioorganic and Medicinal Chemistry
, vol.11
, Issue.9
, pp. 2007-2018
-
-
Gazit, A.1
Yee, K.2
Uecker, A.3
Bohmer, F.-D.4
Sjoblom, T.5
Ostman, A.6
Waltenberger, J.7
Golomb, G.8
Banai, S.9
Heinrich, M.C.10
Levitzki, A.11
-
77
-
-
33846019211
-
EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation
-
DOI 10.1182/blood-2006-04-013805
-
Pan J, Quintas-Cardama A, Kantarjian HM, et al. EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation. Blood. 2007; 109: 315-322. (Pubitemid 46053072)
-
(2007)
Blood
, vol.109
, Issue.1
, pp. 315-322
-
-
Pan, J.1
Quintas-Cardama, A.2
Kantarjian, H.M.3
Akin, C.4
Manshouri, T.5
Lamb, P.6
Cortes, J.E.7
Tefferi, A.8
Giles, F.J.9
Verstovsek, S.10
-
78
-
-
9444258068
-
Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970
-
DOI 10.1182/blood-2004-06-2189
-
Corbin A, Griswold IJ, La Rosee P, et al. Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970. Blood. 2004; 104: 3754-3757. (Pubitemid 39564454)
-
(2004)
Blood
, vol.104
, Issue.12
, pp. 3754-3757
-
-
Corbin, A.S.1
Griswold, I.J.2
La Rosee, P.3
Yee, K.W.H.4
Heinrich, M.C.5
Reimer, C.L.6
Druker, B.J.7
Deininger, M.W.N.8
-
79
-
-
40949134736
-
Thalidomide in advanced mastocytosis
-
DOI 10.1111/j.1365-2141.2008.07038.x
-
Damaj G, Bernit E, Ghez D, et al. Thalidomide in advanced mastocytosis. Br J Haematol. 2008; 141: 249-253. (Pubitemid 351406215)
-
(2008)
British Journal of Haematology
, vol.141
, Issue.2
, pp. 249-253
-
-
Damaj, G.1
Bernit, E.2
Ghez, D.3
Claisse, J.-F.4
Schleinitz, N.5
Harle, J.-R.6
Canioni, D.7
Hermine, O.8
-
81
-
-
0034981905
-
Utility of flow cytometric analysis of mast cells in the diagnosis and classification of adult mastocytosis
-
DOI 10.1016/S0145-2126(01)00050-9, PII S0145212601000509
-
Escribano L, Diaz-Agustin B, Bellas C, et al. Utility of flow cytometric analysis of mast cells in the diagnosis and classification of adult mastocytosis. Leuk Res. 2001; 25: 563-570. (Pubitemid 32506763)
-
(2001)
Leukemia Research
, vol.25
, Issue.7
, pp. 563-570
-
-
Escribano, L.1
Diaz-Agustin, B.2
Bellas, C.3
Navalon, R.4
Nunez, R.5
Sperr, W.R.6
Schernthaner, G.-H.7
Valent, P.8
Orfao, A.9
-
83
-
-
77249148838
-
Treatment of aggressive systemic mastocytosis with daclizumab
-
Quintas-Cardama A, Amin HM, Kantarjian H, Verstovsek S,. Treatment of aggressive systemic mastocytosis with daclizumab. Leuk Lymphoma. 2010; 51: 540-542.
-
(2010)
Leuk Lymphoma.
, vol.51
, pp. 540-542
-
-
Quintas-Cardama, A.1
Amin, H.M.2
Kantarjian, H.3
Verstovsek, S.4
-
84
-
-
76349119028
-
Experience with everolimus (RAD001), an oral mammalian target of rapamycin inhibitor, in patients with systemic mastocytosis
-
Parikh SA, Kantarjian HM, Richie MA, Cortes JE, Verstovsek S,. Experience with everolimus (RAD001), an oral mammalian target of rapamycin inhibitor, in patients with systemic mastocytosis. Leuk Lymphoma. 2010; 51: 269-274.
-
(2010)
Leuk Lymphoma.
, vol.51
, pp. 269-274
-
-
Parikh, S.A.1
Kantarjian, H.M.2
Richie, M.A.3
Cortes, J.E.4
Verstovsek, S.5
-
85
-
-
0029873587
-
JAK2 is associated with the c-kit proto-oncogene product and is phosphorylated in response to stem cell factor
-
Weiler SR, Mou S, DeBerry CS, et al. JAK2 is associated with the c-kit proto-oncogene product and is phosphorylated in response to stem cell factor. Blood. 1996; 87: 3688-3693. (Pubitemid 26129596)
-
(1996)
Blood
, vol.87
, Issue.9
, pp. 3688-3693
-
-
Weiler, S.R.1
Mou, S.2
DeBerry, C.S.3
Keller, J.R.4
Ruscetti, F.W.5
Ferris, D.K.6
Longo, D.L.7
Linnekin, D.8
-
86
-
-
77954659778
-
Inhibition of JAK-STAT signaling by TG101348: A novel mechanism for inhibition of KITD816V-dependent growth in mast cell leukemia cells
-
Lasho T, Tefferi A, Pardanani A,. Inhibition of JAK-STAT signaling by TG101348: a novel mechanism for inhibition of KITD816V-dependent growth in mast cell leukemia cells. Leukemia. 2010; 24: 1378-1380.
-
(2010)
Leukemia.
, vol.24
, pp. 1378-1380
-
-
Lasho, T.1
Tefferi, A.2
Pardanani, A.3
-
87
-
-
73949158887
-
Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: Role of KIT D816V and effects of various targeted drugs
-
Aichberger KJ, Gleixner KV, Mirkina I, et al. Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs. Blood. 2009; 114: 5342-5351.
-
(2009)
Blood.
, vol.114
, pp. 5342-5351
-
-
Aichberger, K.J.1
Gleixner, K.V.2
Mirkina, I.3
-
88
-
-
23744515285
-
Stem cell factor promotes mast cell survival via inactivation of FOXO3a-mediated transcriptional induction and MEK-regulated phosphorylation of the proapoptotic protein Bim
-
DOI 10.1182/blood-2004-12-4792
-
Moller C, Alfredsson J, Engstrom M, et al. Stem cell factor promotes mast cell survival via inactivation of FOXO3a-mediated transcriptional induction and MEK-regulated phosphorylation of the proapoptotic protein Bim. Blood. 2005; 106: 1330-1336. (Pubitemid 41129597)
-
(2005)
Blood
, vol.106
, Issue.4
, pp. 1330-1336
-
-
Moller, C.1
Alfredsson, J.2
Engstrom, M.3
Wootz, H.4
Xiang, Z.5
Lennartsson, J.6
Jonsson, J.-I.7
Nilsson, G.8
-
89
-
-
72249112779
-
Selective RNAi-mediated inhibition of mutated c-kit
-
Ruano I, Izquierdo M,. Selective RNAi-mediated inhibition of mutated c-kit. J RNAi Gene Silencing. 2009; 5: 339-344.
-
(2009)
J RNAi Gene Silencing.
, vol.5
, pp. 339-344
-
-
Ruano, I.1
Izquierdo, M.2
-
90
-
-
72249084733
-
Combination of KIT gene silencing and tocopherol succinate may offer improved therapeutic approaches for human mastocytosis
-
Ruano I, Gargini R, Izquierdo M,. Combination of KIT gene silencing and tocopherol succinate may offer improved therapeutic approaches for human mastocytosis. Br J Haematol. 2010; 148: 59-68.
-
(2010)
Br J Haematol.
, vol.148
, pp. 59-68
-
-
Ruano, I.1
Gargini, R.2
Izquierdo, M.3
-
91
-
-
67449095163
-
Activity of triptolide against human mast cells harboring the kinase domain mutant KIT
-
Jin Y, Chen Q, Shi X, et al. Activity of triptolide against human mast cells harboring the kinase domain mutant KIT. Cancer Sci. 2009; 100: 1335-1343.
-
(2009)
Cancer Sci.
, vol.100
, pp. 1335-1343
-
-
Jin, Y.1
Chen, Q.2
Shi, X.3
-
92
-
-
73949151915
-
The antitumor activity of homoharringtonine against human mast cells harboring the KIT D816V mutation
-
Jin Y, Lu Z, Cao K, et al. The antitumor activity of homoharringtonine against human mast cells harboring the KIT D816V mutation. Mol Cancer Ther. 2010; 9: 21-23.
-
(2010)
Mol Cancer Ther.
, vol.9
, pp. 21-23
-
-
Jin, Y.1
Lu, Z.2
Cao, K.3
-
93
-
-
52049125709
-
The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors
-
Lin TY, Bear M, Du Z, et al. The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors. Exp Hematol. 2008; 36: 1266-1277.
-
(2008)
Exp Hematol.
, vol.36
, pp. 1266-1277
-
-
Lin, T.Y.1
Bear, M.2
Du, Z.3
|